Cogent Biosciences, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 54.37 million compared to USD 39.62 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.56 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.765 USD | +0.06% | +10.32% | +30.02% |
07/05 | Cogent Biosciences Q1 Loss Widens | MT |
07/05 | Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.02% | 742M | |
+3.72% | 106B | |
+7.02% | 23.47B | |
-14.82% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.77% | 16.78B | |
+4.99% | 14.41B | |
+35.62% | 12.86B | |
+323.80% | 8.78B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023